In a phase I study (NCT02410733), FixVac, a complex of RNA/lipoplexes against malignant melanoma TAAs New York-ESO 1, tyrosinase, melanoma-associated antigen A3 (MAGE-A3), and trans-membrane phosphatase with tensin homology (TPTE) showed the metabolic activity of the spleen increased post the sixth immunization, indicating the targeted delivery of an mRNA-LNP encoding four non-mutated melanoma antigens and activation of resident immune cells (156). This evidence concerns the gene TYR and melanoma.